John S Macdonald
Affiliation: St. Vincent's Comprehensive Cancer Center
- Chemotherapy in the management of gastric cancerJohn S Macdonald
St Vincent s Comprehensive Cancer Center, 325 West 15th St, New York, NY 10011, USA
J Clin Oncol 21:276s-279s. 2003
- A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) studyJohn S Macdonald
St Vincent s Comprehensive Cancer Center, 325 W 15th Street, New York, NY 10011, USA
Invest New Drugs 23:485-7. 2005..Median survival was 2.6 months (mo) (95% CI 2.1-3.6), 6-mo survival is 19% (95% CI, 8-29%), median time to treatment failure was 1.4 mo (95% GI 1.1-1.6). R115777 is ineffective as monotherapy in advanced pancreatic cancer...
- Clinical overview: adjuvant therapy of gastrointestinal cancerJohn S Macdonald
St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY 10011, USA
Cancer Chemother Pharmacol 54:S4-11. 2004..Such tumors represent about 15% of all colon cancers and have an improved outcome when compared to those not expressing MSI, and may not benefit from adjuvant chemotherapy...
- Role of post-operative chemoradiation in resected gastric cancerJohn S Macdonald
Saint Vincent s Comprehensive Cancer Center, New York, New York 10011, USA
J Surg Oncol 90:166-70. 2005..Future advances in the therapy of resectable gastric cancer may come from studies of pre-operative neoadjuvant chemoradiation and the application of targeted therapies such as growth receptor antagonists and anti-angiogenesis agents...
- Adjuvant therapy for gastric cancerJohn S Macdonald
Department of Gastrointestinal Oncology, St Vincent s Comprehensive Cancer Center, New York, NY, USA
Semin Oncol 30:19-25. 2003..Future advances in the therapy for resectable gastric cancer may come from studies of preoperative neoadjuvant chemoradiation and the application of targeted therapies such as growth receptor antagonists and anti-angiogenesis agents...
- Advances in the therapy of gastric cancerJohn S Macdonald
Saint Vincents Comprehensive Cancer Center, 325 West 15th Street, New York, New York 10011, USA
Gastric Cancer 5:35-40. 2002..Substantial improvements in outcome are likely to depend on the integration into multimodality strategies of novel, molecularly targeted agents in all stages of gastric cancer treatment...
- Treatment of localized gastric cancerJohn S Macdonald
Gastrointestinal Oncology Service, Saint Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
Semin Oncol 31:566-73. 2004..Future advances in the therapy of resectable gastric cancer may come from studies of preoperative neoadjuvant chemoradiation and the application of targeted therapies such as growth receptor antagonists and antiangiogenesis agents...
- Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tractReshma L Mahtani
St Voncent s Comprehensive Cancer Cernter, New York, New York, USA
Oncologist 13:39-50. 2008..This review discusses recent clinical studies that have further defined this synergy, focusing primarily on tumors of the gastrointestinal tract...
- Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 StudyJeffrey A Meyerhardt
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 22:166-74. 2004..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain...
- Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group StudySusan G Urba
University of Michigan Medical Center, Ann Arbor, MI 48109 0922, USA
Invest New Drugs 22:91-7. 2004..Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer...
- An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomachSung Kim
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Kangnam Gu, Seoul, South Korea
Int J Radiat Oncol Biol Phys 63:1279-85. 2005..We investigated the effect of postoperative chemoradiotherapy on the relapse rate and survival rate of patients with D2-resected gastric cancer...
- Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114Jeffrey A Meyerhardt
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 22:648-57. 2004..To study the relationship between body mass index (BMI) and rates of sphincter-preserving operations, overall survival, cancer recurrence, and treatment-related toxicities in patients with rectal cancer...
- Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinomaKari Chansky
Southwest Oncology Group Statistical Center, Seattle, Washington, USA
Cancer 103:1165-71. 2005..The patient populations from 4 Southwest Oncology Group colorectal carcinoma trials with 5-FU-containing regimens were examined for toxicity differences between the genders...
- Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodesAdam C Berger
Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
J Clin Oncol 23:8706-12. 2005..Colorectal cancer is the second leading cause of cancer deaths in the United States, with poor survival predicted by regional lymph node (LN) metastasis. The impact of LN ratio (LNR) on survival is unknown in this disease...
- A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group studyRobert P Whitehead
University of Texas Medical Branch, Galveston, TX, USA
Invest New Drugs 22:467-73. 2004..The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in patients with advanced colorectal cancer...
- Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group studyCynthia G Leichman
Comprehensive Cancer Center, Desert Regional Medical Center, Palm Springs, CA 92262, USA
Clin Colorectal Cancer 5:119-23. 2005..A companion trial was funded to assess molecular parameters associated with fluoropyrimidine response or resistance and toxicity from these treatments...
- Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancerElizabeth A Poplin
Operations Office, 14980 Omicron Dr, San Antonio, TX 78245 3217, USA
J Clin Oncol 23:1819-25. 2005....
- Impact of diabetes mellitus on outcomes in patients with colon cancerJeffrey A Meyerhardt
Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 21:433-40. 2003..To determine the influence of diabetes mellitus on long-term outcomes and treatment-related toxicity among patients with curatively resected colon cancer...
- Gastric cancer--new therapeutic optionsJohn S Macdonald
N Engl J Med 355:76-7. 2006
- Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup studyM Margaret Kemeny
Cancer Center of Queens, Queens Hospital Center, Jamaica, Queens, NY 11432, USA
J Clin Oncol 20:1499-505. 2002....
- Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatmentScott A Hundahl
Queen s Cancer Institute, Honolulu, Hawaii 96813, USA
Ann Surg Oncol 9:278-86. 2002..Intergroup 0116 (Southwest Oncology Group 9008), a national, multicenter, two-armed, prospective, randomized trial of adjuvant postoperative chemoradiotherapy, has demonstrated significant benefit...
- A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group StudyRobert P Whitehead
University of Texas Medical Branch, Galveston, TX, USA
Invest New Drugs 22:335-41. 2004..The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in patients with advanced pancreatic cancer...
- Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700William H Isacoff
University of California, Los Angeles Medical Center, Los Angeles, CA, USA
J Clin Oncol 25:1665-9. 2007..To test the hypothesis that dual biochemical modulation of fluorouracil (FU) in combination with mitomycin improves the survival of patients with pancreas cancer...
- A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) TrialAkira Tsuburaya
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahi ku, Yokohama 2410815, Japan
Jpn J Clin Oncol 35:672-5. 2005..This trial could appraise sequential combination therapy and efficacy of new drugs as adjuvant for gastric cancer treatment...
- Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancerCynthia G Leichman
Comprehensive Cancer Centers of the Desert, Palm Springs, CA 92262, USA
Invest New Drugs 20:419-24. 2002....
- Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144Stephen R Smalley
Kansas City Community Clinical Oncology Program CCOP, Kansas City, KS, USA
J Clin Oncol 24:3542-7. 2006..Adjuvant chemoradiotherapy after or before resection of high-risk rectal cancer improves overall survival (OS) and pelvic control. We studied three postoperative fluorouracil (FU) radiochemotherapy regimens...
- Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinomaJeffrey A Meyerhardt
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 98:484-95. 2003..Obesity is a risk factor for the development of colon carcinoma. The influence of body mass index (BMI) on long-term outcomes and treatment-related toxicity in patients with colon carcinoma has not been well characterized...
- Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group studyJames H Doroshow
Division of Cancer Treatment and Diagnosis, National Cancer Institute, City of Hope National Medical Center, Duarte, CA, USA
Invest New Drugs 24:537-42. 2006..2 months. The ability to safely deliver twice the usual dose of 5-FU with leucovorin on a weekly schedule suggests that oral uridine analog supplementation with PN401 may enhance the therapeutic index of the fluoropyrimidines...
- ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancerGershon Y Locker
American Society of Clinical Oncology Tumor Markers Expert Panel, Alexandria, VA 22314, USA
J Clin Oncol 24:5313-27. 2006..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of gastrointestinal cancers...
- Impact of hospital volume on recurrence and survival after surgery for gastric cancerPeter C Enzinger
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Ann Surg 245:426-34. 2007..However, because such data may be significantly influenced by the impact of postoperative mortality, and may be imbalanced for factors important to survival, the true nature of this relationship remains uncertain...
- Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group studyRobert P Whitehead
Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
Invest New Drugs 24:335-41. 2006..The purpose of this Phase II multi-institutional trial was to determine the efficacy and toxicity of R115777 in previously untreated patients with metastatic colorectal carcinoma...
- Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trialWilliam F Regine
Department of Radiation Oncology, University of Maryland Medical Center, Baltimore 21030, USA
JAMA 299:1019-26. 2008..Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil...
- Gastric cancer: D2 dissection or low Maruyama Index-based surgery--a debateHarold O Douglass
State University of New York at Buffalo, Capen Hall, Buffalo, NY 14260, USA
Surg Oncol Clin N Am 16:133-55. 2007..The premise of this approach is that extended gastrectomy with D2 lymph node dissection is good. Also addressed are prognostic and predictive factors in the surgical treatment of stomach cancer...
- Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089Daniel G Haller
University of Pennsylvania, Philadelphia, PA, USA
J Clin Oncol 23:8671-8. 2005..Intergroup (INT) 0089 assessed the relative contributions of leucovorin and levamisole in such patients...
- Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancerA David McCollum
A D McCollum, R J Mayer, C S Fuchs, Dana Farber Cancer Institute, Boston, MA, USA
J Natl Cancer Inst 94:1160-7. 2002..In this study, we examined survival and toxic effects among African-American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer...
- Oxaliplatin: new opportunities for the treatment of gastrointestinal cancerJohn S Macdonald
Cancer Invest 20:287-9. 2002
- Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson
Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
Int J Radiat Oncol Biol Phys 54:386-96. 2002..To determine the rates of survival and disease control by TNM and MAC stage in three randomized North American rectal adjuvant studies...
- Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trialRobert C Miller
North Central Cancer Treatment Group, Coordinating Center, Rochester, MN, USA
Int J Radiat Oncol Biol Phys 54:409-13. 2002..Toxicity from a previously reported randomized clinical trial was analyzed to quantify the difference in this risk. Additionally, the persistence of diarrhea after RT was analyzed...
- Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group studyCary A Presant
Los Angeles Oncologic Institute, St Vincent Medical Center, CA, USA
Invest New Drugs 20:369-76. 2002..The first 19F-MRS was following 5-FU 600 mg/m2 alone, and the second 19F-MRS was following by leucovorin 500 mg/m2 and then 5-FU 600 mg/m2...
- Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089Robert J Green
The Helen and Harry Gray Cancer Institute, 1309 North Flagler Drive, West Palm Beach, FL 33401, USA
Ann Intern Med 136:261-9. 2002..It is unclear whether guidelines for colonoscopy screening in patients with polyps are appropriate for patients with previous colon cancer...
- Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resectionNatalie E Joseph
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Ann Surg Oncol 10:213-8. 2003..Correct determination of nodal status is pivotal to accurate staging and predicting survival...
- Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrenceJeffrey A Meyerhardt
Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Ann Intern Med 139:649-57. 2003..However, because such administrative data lack information on cancer recurrence, the true nature of this relation remains uncertain...
- Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lectureJoseph M Unger
Southwest Oncology Group Statistical Center and the Puget Sound Oncology Consortium, Seattle, WA, USA
J Clin Oncol 21:246s-252s. 2003..Meanwhile the prevention of cancer has received less attention...
- Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson
Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
J Clin Oncol 22:1785-96. 2004..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies...
- Vive la difference: sex and fluorouracil toxicityJohn S Macdonald
J Clin Oncol 20:1439-41. 2002